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AbstrACt
Introduction Necrotising enterocolitis (NEC) is a 
potentially devastating neonatal disease. A temporal 
association between red cell transfusion and NEC is well 
described. Observational data suggest that withholding 
enteral feeds around red cell transfusions may reduce the 
risk of NEC but this has not been tested in randomised 
trials; current UK practice varies. Prevention of NEC is a 
research priority but no appropriately powered trials have 
addressed this question. The use of a simplified opt-out 
consent model and embedding trial processes within 
existing electronic patient record (EPR) systems provide 
opportunities to increase trial efficiency and recruitment.
Methods and analysis We will undertake a randomised, 
controlled, multicentre, unblinded, pilot trial comparing 
two care pathways: continuing milk feeds (before, during 
and after red cell transfusions) and withholding milk 
feeds (for 4 hours before, during and for 4 hours after 
red cell transfusions), with infants randomly assigned 
with equal probability. We will use opt-out consent. A 
nested qualitative study will explore parent and health 
professional views. Infants will be eligible if born at <30+0 
gestational weeks+days. Primary feasibility outcomes 
will be rate of recruitment, opt-out, retention, compliance, 
data completeness and data accuracy; clinical outcomes 
will include mortality and NEC. The trial will recruit in two 
neonatal networks in England for 9 months. Data collection 
will continue until all infants have reached 40+0 corrected 
gestational weeks or neonatal discharge. Participant 
identification and recruitment, randomisation and all trial 
data collection will be embedded within existing neonatal 
EPR systems (BadgerNet and BadgerEPR); outcome data 
will be extracted from routinely recorded data held in the 
National Neonatal Research Database.
Ethics and dissemination This study holds Research 
Ethics Committee approval to use an opt-out approach 
to consent. Results will inform future EPR-embedded 
and data-enabled trials and will be disseminated through 
conferences, publications and parent-centred information.
trial registration number ISRCTN registry 
ISRCTN62501859; Pre-results.
bACkground
Necrotising enterocolitis (NEC) is among the 
most potentially devastating neonatal diseases 
and has a mortality of up to 33%, the most 
severe form (requiring surgery or resulting 
in death) affects about 5% of infants born at 
strengths and limitations of this study
 ► Necrotising enterocolitis (NEC) is a rare but poten-
tially devastating neonatal disease, occurring pre-
dominantly in the most preterm infants. Neonatal 
trials to-date have not been adequately powered to 
detect realistic reductions in NEC.
 ► In this prospective, randomised pilot trial we will 
evaluate the feasibility of a data-enabled neonatal 
trial with processes embedded within an existing 
electronic patient record (EPR) system; accuracy 
and completeness of trial data will be validated at 
source.
 ► In this individually randomised, comparative effec-
tiveness trial we will pilot opt-out consent and ex-
plore parent and health professional views of this 
approach in a nested qualitative study.
 ► We will evaluate the feasibility of EPR-embedded 
randomised comparative-effectiveness trials using a 
simplified opt-out consent for efficient, quicker and 
less resource burdensome neonatal trials at scale.
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<30 gestational weeks1; survivors are at high risk of long-
term health2 and developmental problems.3 4 Prevention 
of NEC has been identified as one of the most important 
research uncertainties in the field of preterm birth.5 
The pathogenesis of NEC is incompletely understood, 
however a temporal association between red cell transfu-
sion and the subsequent development of the disease is 
well described.6 7 This ‘transfusion associated NEC’ may 
be more severe8 with higher mortality.9 10 The mechanism 
thought to underpin this relationship links milk feeds 
and packed red cell transfusion to NEC through altered 
mesenteric blood flow and intestinal barrier function; 
this is supported by animal1112 and human studies13 14 15. 
Understanding the link between NEC and blood transfu-
sion is of particular importance given that almost all very 
preterm babies will have a red cell transfusion and many 
will receive multiple transfusions16.
Stopping milk feeds around the time of packed red 
cell transfusion is currently practised in some neonatal 
settings to reduce the risk of NEC, putatively by main-
taining more physiological intestinal blood flow.17 This 
practice has not, however, been tested in an adequately 
powered randomised trial, and there are physiological 
reasons why stopping milk feeds in preterm infants may 
lead to harm. Interrupting enteral feeding prolongs the 
time taken to reach full milk feeds, which is associated with 
invasive infection18, and may paradoxically be associated 
with an increased risk of NEC 19. One small, single-centre 
randomised pilot trial has assessed withholding enteral 
feeds around red cell transfusion but was underpowered 
to detect a difference in NEC.20 A systematic review of 
observational studies21 identified seven historical control 
studies including 7492 preterm infants; these studies were 
at high risk of bias including regression to the mean and 
ascertainment bias. Pooled results found an association 
between withholding feeds in the peritransfusion period 
and a reduced risk of NEC. The authors concluded that 
adequately powered randomised controlled trials are 
needed to confirm these findings.
There is considerable variation in current UK practice 
in relation to withholding enteral feeds during packed 
red cell transfusion in preterm infants: a 2011 survey of 
UK neonatal units (68% response rate) demonstrated 
that 35% of UK units routinely withheld enteral feeds 
during packed red cell transfusion.22
If withholding enteral feeds around the time of packed 
red cell transfusion reduces the risk of NEC, then imple-
menting this simple practice will reduce the mortality 
and long-term complications of NEC. Conversely, if the 
safety of continued feeding can be demonstrated, this will 
facilitate increased and consistent feeding with breast-
milk, which has well described short-term and long-term 
benefits.
NEC is rare and occurs at a higher incidence in the 
most preterm infants and so trials targeting NEC need a 
large number of very preterm infants, who are themselves 
rare. As a result, no previous trial has been powered to 
look at NEC and there is no intervention to prevent NEC 
supported by high-quality randomised evidence. Methol-
ogies that have been proposed to improve efficiency and 
recruitment into randomised trials include the use of 
simplified opt-out approaches to consent,23 and embed-
ding trial processes into existing electronic patient record 
(EPR) systems.24
The objectives of this pilot trial are:
1. To determine whether a large multicentre trial address-
ing the following question is feasible: among preterm in-
fants (patient), does the practice of withholding enteral feeds 
around the time of blood transfusion (intervention), compared 
with continued enteral feeding around the time of blood trans-
fusion (comparator), lead to a reduction in severe necrotising 
enterocolitis (outcome)?
2. To determine whether clinical trial processes (identi-
fying participants, randomisation and data collection) 
can be successfully integrated into existing neonatal 
EPR systems, and whether trial data can be extracted 
from routinely recorded clinical data held in the Na-
tional Neonatal Research Database (NNRD).
3. To determine whether using a simplified opt-out con-
sent process is feasible and acceptable to parents and 
health professionals.
MEthods
design
The WHEAT trial is a randomised controlled, unblinded, 
multicentre, pilot trial comparing two care pathways. 
The primary metrics of feasibility are recruitment, data 
completeness and data accuracy; clinical outcomes 
include mortality and NEC. Infants will be randomised 
with a 1:1 allocation ratio (using permuted blocks of vari-
able size), stratified within neonatal unit by gestational age 
at birth and infant sex. Trial processes will be embedded 
within neonatal EPR systems and all outcome data will be 
extracted from data that are routinely recorded within 
the existing neonatal EPR systems (BadgerNet and 
BadgerEPR), and held in the NNRD.
The trial will recruit infants from neonatal units within 
two neonatal networks in England: Northwest London 
Neonatal Network and Southern West Midlands Neonatal 
Operational Delivery Network. Recruitment will be for 
9 months (15 October 2018 to 30 June 2019), with data 
collection continuing for a further 3 months, until all 
trial infants have finished follow-up at 40+0 corrected 
gestational weeks or neonatal discharge if sooner.
Eligibility criteria
Inclusion criteria:
1. Preterm birth at <30+0 gestational weeks+days.
Exclusion criteria:
1. Parent(s) opted out of trial participation.
2. Packed red cell transfusion with concurrent enteral 
feeds prior to enrolment. (Infants who have received 
a packed red cell transfusion while nil-by-mouth are el-
igible; buccal colostrum will not be counted as enteral 
feeding.)
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3. Infants where enteral feeding is contraindicated in the 
first 7 days after birth (eg, congenital abnormality).
Interventions
Both comparator pathways of care are standard in the 
UK; the WHEAT trial is a pilot comparative effectiveness 
trial. The two care pathways that will be compared are:
1. Withholding feeds around transfusion: all enteral 
feeds will be discontinued (the infant will be placed 
nil by mouth) for a period of 4 hours prior to packed 
red cell transfusion, during the packed red cell trans-
fusion and until 4 hours post packed red cell transfu-
sion. During this period (~12 hours), hydration and 
blood glucose will be maintained according to local 
practice, commonly by provision of parenteral nutri-
tion or intravenous dextrose. Four hours after the red 
cell transfusion has finished, feeds will be restarted in 
the manner in which they were being received prior 
to the decision to transfuse. This duration of with-
holding feeds will follow the approach used in other 
trials20 and observational studies,21 and identified to 
be the most acceptable in a survey of UK neonatal 
units.
2. Continuing feeds around transfusion: enteral feeds 
will continue to be given prior, during and after the 
packed red cell transfusion, in the manner in which 
they were being given prior to the decision to transfuse.
Infants will remain allocated to the same care pathway 
until 34+6 weeks+days gestational age.
In order to ensure that this pragmatic trial is as gener-
alisable as possible to current practice, blood transfusions 
will be administered when clinically indicated according 
to local packed red cell transfusion guidelines. Data will 
be collected about pretransfusion haemoglobin level for 
trial participants. Other concomitant care, including 
speed of increase of enteral feeds and choice of milk, for 
both the withholding feeds around transfusion pathway 
and the continuing feeds around transfusion pathway of 
care will be according to locally defined practice.
outcomes
Feasibility outcomes:
1. Recruitment: proportion of infants <30 weeks of gesta-
tion admitted whose parents agree to trial involvement 
and the infant is randomised in the WHEAT trial.
2. Retention: proportion of of recruited infants where 
outcome data are available up to the end of the fol-
low-up period.
3. Compliance: proportion of recruited infants who cor-
rectly received their allocated care pathway around all 
packed red cell transfusions between randomisation 
and 34+6 gestational weeks+days.
4. Data completeness: proportion of missing data for 
each data item reported as a baseline characteristic or 
an outcome.
5. Data accuracy: proportion of cases where the following 
data items are correctly recorded when compared with 
source data (clinical notes or EPR data).
a. Severe NEC: all infants who had a diagnosis of 
non-severe NEC and a random sample of 25% of in-
fants who did not have a diagnosis of NEC will have 
their source data verified to ensure that they do not 
meet the criteria for severe NEC; 25% was selected 
for pragmatic reasons.
b. Spontaneous intestinal perforation.
c. All-cause mortality.
d. Central line associated blood stream infection.
Clinical outcomes:
All clinical outcomes will be assessed from randomisa-
tion to 40+0 weeks of gestation or neonatal unit discharge, 
whichever occurs first.
1. Severe NEC: histologically or surgically confirmed, or 
recorded in part 1 the death certificate. These infants 
will be identified as described in Battersby et al,25 which 
will include infants recorded as being transferred for 
surgery
2. Spontaneous intestinal perforation: histologically or 
surgically confirmed, or recorded in part 1 the death 
certificate.
3. All-cause mortality.
4. Total duration of neonatal care in days: including all 
levels of care (intensive care, high dependency care, 
special care and ordinary care).
5. Duration of any parenteral nutrition in days.
6. Number of days with a central venous line in situ.
7. Number of central line associated blood stream infec-
tions defined according to National Neonatal Audit 
Programme 2017 definition26
8. Growth: change in birth weight and head circumfer-
ence for gestational age SD score.
sample size
There is no predefined sample size for this pilot trial. 
Recruitment (absolute numbers and the rate) will be 
a primary outcome for the pilot trial. The estimated 
recruitment target for the pilot trial is up to 250, based 
on predicted infant throughput at participating neonatal 
units and assuming 65%–70% recruitment of eligible 
infants.
data collection
Potential participants will be identified through the 
existing neonatal EPR systems that are widely used across 
England, Scotland and Wales; BadgerNet (a clinical 
summary system) or BadgerEPR (a complete EPR system). 
Baseline data for all infants admitted to neonatal units 
in the UK are routinely entered into the EPR admission 
summary as part of normal clinical care. These data are 
updated in real-time and held securely on BadgerNet and 
BadgerEPR servers. In participating units, data entered 
electronically into the admission summary will be interro-
gated by the EPR platform in real time to identify and 
flag infants meeting the WHEAT trial inclusion criteria. 
When an infant in a participating unit meets the inclu-
sion criteria, this will result in an electronic reminder 
appearing on the EPR platform at the participating 
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unit. This ‘flag’ will inform the health professional that 
the infant is eligible for the WHEAT trial and link to the 
parent information leaflet. The EPR system will use data 
(neonatal unit, gestational age and sex) entered as part of 
the admission summary to stratify infants.
Baseline characteristics and clinical outcomes will be 
extracted from routinely recorded clinical data held in the 
NNRD. The NNRD holds data from all infants admitted to 
National Health Service (NHS) neonatal units in England, 
Scotland and Wales (~90 000 infants annually). Contrib-
uting neonatal units are known as the UK Neonatal Collab-
orative. Data are extracted from point-of-care neonatal 
electronic health records completed by health professionals 
during routine clinical care. A defined data extract, the 
Neonatal Dataset of ~450 data items,27 is transmitted quar-
terly to the Neonatal Data Analysis Unit at Imperial College 
London and Chelsea and Westminster NHS Foundation 
Trust where patient episodes across different hospitals are 
linked and data are cleaned (queries about discrepancies 
and implausible data configurations are fed back to health 
professionals and rectified).28
randomisation
Infants will be randomly assigned to either pathway of 
care in a 1:1 allocation ratio as per a computer-generated 
randomisation sequence using permuted blocks of various 
sizes with stratification as described below. The block sizes 
will not be disclosed to ensure allocation concealment.
Stratification will be by neonatal unit of enrolment and 
using the following categories:
1. Gestational age at birth.
 – <28+0 weeks+days
 – 28+0 to 29+6 weeks+days.
2. Infant sex.
Infants who are part of a multiple birth set (twins, 
triplets or higher order multiples) will be randomised as 
a set to the same pathway of care following feedback from 
parent representatives, parent organisations including 
Bliss and TAMBA (Twins and Multiple Births Association) 
and research involving parents and adult ex-preterm 
twins.29
Allocation concealment
Infants will be randomised using an online secure 
central randomisation system which will be embedded 
into the existing neonatal EPR systems (BadgerNet and 
BadgerEPR). Randomisation will occur within the EPR to 
ensure allocation concealment.
blinding
The WHEAT trial will be unblinded as it is not possible to 
mask the different care pathways.
statistical methods
The planned main WHEAT trial will be based on a supe-
riority hypothesis; however, the pilot trial is not powered 
to detect any differences between the intervention arm 
(withholding feeds) and the comparator arm (continuing 
feeds).
Therefore, no formal statistical hypothesis testing will 
be conducted.
Continuous variables will be summarised using means 
and SD unless their distributions are skewed, in which 
case medians, 25th quartiles, 75th quartiles and the range 
(lowest and highest values) will be presented. Dichot-
omous variables will be presented as frequencies and 
percentages. In addition, 95% CIs will be presented for 
the feasibility outcomes. The recruitment rate will be 
reported for both arms combined, and retention and 
compliance rates will be reported separately by treatment 
arm in addition to both arms combined.
Changes to the statistical analysis described in the original 
protocol
The original protocol is available as supplementary data. 
The following changes to the statistical analysis plan were 
made prior to completion of data collection:
1. The pilot trial will not be performing any comparative 
analysis of outcomes between trial arms, or conducting 
any formal statistical hypothesis testing.
2. The denominator for the recruitment rate will be in-
fants <30 weeks of gestation admitted to recruiting 
sites; the planned denominator (infants who fulfil all 
of the eligibility criteria and whose parents have been 
approached) cannot be used as regulatory approval to 
use these data was not granted.
3. The opt-out rate of parents whose infants are eligible 
for the trial will not be reported as regulatory approval 
to use these data was not granted.
4. Data completeness will be reported for each individual 
data item and not the proportion of eligible infants for 
which trial items are complete.
5. A random sample of 25% of infants who did not have a 
diagnosis of NEC recorded in the EPR system had their 
source data verified to ensure that they did not meet 
the criteria for severe NEC.
6. All outcome events, including duration of hospital stay 
and growth scores, were be measured until neonatal 
unit discharge or 40+0 weeks of gestation, whichever 
occurs first.
steering committee
An independent Trial Steering Committee (TSC) 
appointed by the study sponsor and approved by the 
funder (MRC) will oversee the project. The TSC will 
consist of an independent chair and at least two other 
independent members. The Chief Investigator and Clin-
ical Trials Unit Director will also sit on the TSC.
data monitoring
A Data Monitoring Committee (DMC) independent of 
the applicants and of the TSC will review the progress of 
the trial as agreed and provide advice on the conduct of 
the trial to the TSC and, via the TSC, to the sponsor. The 
DMC will act according to its charter, which will be agreed 
at its first meeting.
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Adverse events
Due to the nature of the patient population, neonates in 
intensive care, a high incidence of adverse events is fore-
seeable during their routine care and treatment. Conse-
quently, only those adverse events identified as serious 
adverse events (SAEs) will be recorded for the trial. 
Unforeseen SAEs and the SAEs associated with the allo-
cated pathway of care must be reported to the Clinical 
Trials Unit by a member of site staff within 24 hours of 
becoming aware of the event. Reporting of SAEs will not 
use existing EPR systems but will use telephone, fax and 
email systems.
registration
This study is registered in ISRCTN.
Parent, patient and public involvement
The WHEAT pilot trial addresses one of the most important 
research uncertainties in preterm birth, as identified 
by over 500 parents, patients, health professionals and 
researchers.5 The WHEAT trial has been developed in 
partnership with parents; protocol author HR is a parent 
with experience of preterm birth and protocol author LC 
represents Bliss, the charity for babies born premature or 
sick; both HR and Bliss have contributed to trial develop-
ment from inception. Over 400 parents and patients have 
contributed to the selection of trial outcomes through 
the COIN project.30 Parents and Bliss have been involved 
in developing the opt-out consent process, how this is 
communicated, in designing information leaflets and 
posters. The WHEAT trial has parent representatives on 
oversight committees to ensure that the trial
Ethics and dissemination
Because both the care pathways that are being compared 
are part of standard UK practice, WHEAT is using a 
simplified model of consent. This means that parents 
will have the WHEAT trial explained to them and will 
be asked to ‘opt out’ if they do not want their infant to 
be randomised and enrolled in the trial. Parents will be 
approached shortly after their infant is admitted to the 
neonatal unit (in most cases within the first 24 hours). 
There is no upper time limit as to when trial discussions 
can take place. Parents will be able to opt out of the 
WHEAT trial at any point. Neonatal health professionals 
will be prompted within the EPR to explain WHEAT to 
parents of eligible infants and to provide them with an 
information leaflet. If parents opt out this will be recorded 
in the EPR. If parents do not opt out and are happy for 
their infant to take part in WHEAT, randomisation will 
occur through the EPR. Enrolment of the infant and the 
allocation will be notified to the local team through the 
EPR. Because of the opt-out nature of WHEAT there will 
not be a signed consent form.
A qualitative exploration of the opt-out consent and 
recruitment process, and trial procedures will be conducted 
following the end of recruitment. Qualitative interviews will 
be undertaken with both parents that consented to the trial 
and health professionals from the recruiting sites.
Due to the common nature of packed red cell trans-
fusion in the trial population (infants born at <30+0 
gestational weeks+days), health professionals will 
explain the WHEAT trial and opt-out process shortly 
after birth (in most cases within the first 24 hours). A 
minority of infants will not receive a packed red cell 
transfusion during their neonatal unit stay. These will 
not be included in the main analysis population of clin-
ical outcomes.
Results will be presented at national and international 
academic conferences and published in peer-reviewed 
scientific publications. Protocol author HR will work 
with the neonatal charity Bliss to produce parent-cen-
tred information for dissemination through social media, 
online and to be distributed on neonatal units.
dIsCussIon
Preventing NEC is a recognised research priority in 
preterm birth5; however, there are no preventative inter-
ventions supported by high quality evidence. One key 
reason is because NEC is a rare condition, therefore any 
trial seeking to detect a realistic reduction in NEC will 
require recruitment and randomisation of more preterm 
infants than ever previously achieved. For example, 
a trial seeking to detect a 25% relative risk reduction 
in NEC from a background rate of 6%26 would need 
to randomise over 9000 infants to have 90% power to 
detect such a difference with a two-sided 5% significance 
level. The largest previous individually randomised trial 
that included preterm infants was the INIS trial31 which 
enrolled 3493 infants. Undertaking neonatal trials on 
this scale will be challenging; for such large trials to be 
funded and sustainable, they will need to be more effi-
cient, less burdensome and international in scope. There 
are successful examples of large simple trials in other 
specialties that can inform neonatal practice: the TASTE 
trial32 demonstrated high efficiency and low burden by 
integrating trial processes within an existing data capture 
system, and the TRANSFUSE trial33 demonstrated 
very high recruitment rates (>75%) through the use of 
opt-out models of consent. The WHEAT pilot trial will 
apply these approaches and measure their feasibility and 
acceptability in neonatal care. If these methodologies can 
be successfully applied, they will facilitiate efficient, large, 
simple trials suitable to address the many clinical uncer-
tainties the plague neonatal care.34
The WHEAT pilot trial will determine the feasibility of 
addressing an important clinical question regarding the 
optimal approach to feeding preterm infants around the 
time of red cell transfusions, in preparation for a future 
definitive trial. Currently, there is insufficient evidence to 
recommend withholding or continuing milk feeds around 
red cell transfusion in preterm infants because available 
physiological and observational data are inconclusive.
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strength and limitations
The proposed trial has a number of strengths. The 
robustness of core NNRD data (birth weight, sex, length 
of stay and death) have been previously demonstrated for 
research purposes,1 35 36 this pilot trial will prospectively 
evaluate their accuracy and completeness for clinical 
trials. The trial will evaluate the feasibility of recruiting 
infants across two neonatal networks, including smaller 
neonatal units that do not traditionally recruit into 
neonatal randomised trials. Limitations include the 
unblinded nature of the trial and the use of a potentially 
subjective primary outcome, NEC. We endeavoured to 
mitigate against these through use of a previously vali-
dated, objective definition for NEC.1
ConClusIon
Neonatal trials to date have been unable to robustly eval-
uate strategies to prevent major preterm morbidities, 
such as optimal feeding around transfusion to prevent 
NEC, because of the large sample sizes required. This 
protocol describes a prospective, randomised controlled 
pilot trial to evaluate trial methodologies aiming to effi-
ciently address such neonatal uncertainties.
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